Theratechnologies Inc. (NASDAQ:THTX) Sees Large Growth in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a significant growth in short interest in the month of August. As of August 15th, there was short interest totaling 300,200 shares, a growth of 31.4% from the July 31st total of 228,400 shares. Based on an average daily volume of 484,300 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.8% of the company’s shares are sold short. Approximately 0.8% of the company’s shares are sold short. Based on an average daily volume of 484,300 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Ratings Changes

Separately, Jones Trading lowered shares of Theratechnologies from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 3rd. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Theratechnologies has an average rating of “Buy”.

Institutional Investors Weigh In On Theratechnologies

A number of institutional investors have recently made changes to their positions in THTX. Stonepine Capital Management LLC increased its position in shares of Theratechnologies by 632.0% during the second quarter. Stonepine Capital Management LLC now owns 189,051 shares of the company’s stock valued at $446,000 after acquiring an additional 163,226 shares during the last quarter. Alberta Investment Management Corp acquired a new stake in shares of Theratechnologies during the second quarter valued at about $354,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Theratechnologies during the second quarter valued at about $313,000. Rangeley Capital LLC acquired a new stake in shares of Theratechnologies during the second quarter valued at about $118,000. Finally, Cyndeo Wealth Partners LLC acquired a new stake in shares of Theratechnologies during the first quarter valued at about $42,000.

Theratechnologies Price Performance

Shares of THTX stock opened at $3.27 on Wednesday. Theratechnologies has a 1-year low of $1.12 and a 1-year high of $3.28. The firm has a market cap of $150.35 million, a PE ratio of -17.21 and a beta of 0.51. The company has a 50-day moving average of $3.18 and a two-hundred day moving average of $2.54.

Theratechnologies (NASDAQ:THTX) last announced its quarterly earnings results on Wednesday, July 9th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.08). The business had revenue of $17.73 million for the quarter, compared to analyst estimates of $24.30 million. Sell-side analysts anticipate that Theratechnologies will post 0.01 EPS for the current fiscal year.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.